EC
VERV

EcoR1 Capital’s Verve Therapeutics VERV Stock Holding History

EcoR1 Capital’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,250,000
Closed -$5.71M – 50
2025
Q1 		$5.71M Hold
1,250,000
– – 0.34% 29
2024
Q4 		$7.05M Hold
1,250,000
– – 0.27% 42
2024
Q3 		$6.05M Hold
1,250,000
– – 0.21% 45
2024
Q2 		$6.1M Hold
1,250,000
– – 0.19% 45
2024
Q1 		$16.6M Hold
1,250,000
– – 0.42% 39
2023
Q4 		$17.4M Buy
+1,250,000
New +$15.5M 0.45% 33
2022
Q3 		– Sell
-98,593
Closed -$1.51M – 86
2022
Q2 		$1.51M Hold
98,593
– – 0.05% 62
2022
Q1 		$2.25M Sell
98,593
-1,407
-1% -$40.2K 0.07% 62
2021
Q4 		$3.69M Hold
100,000
– – 0.12% 53
2021
Q3 		$4.7M Hold
100,000
– – 0.16% 44
2021
Q2 		$6.03M Buy
+100,000
New +$4.15M 0.23% 40

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

EcoR1 Capital's VERV Position: Q2 2025 in Review

EcoR1 Capital sold out of Verve Therapeutics (VERV) in Q2 2025, closing a stake of 1,250,000 shares — an estimated $5.71M sold.

EcoR1 Capital first reported a position in VERV in Q2 2021 and held it in 11 quarters. The position peaked at $17.4M in Q4 2023. 175 funds tracked by Wall St. Rank hold VERV as of Q2 2025.

  • EcoR1 Capital reported no remaining Verve Therapeutics position as of Q2 2025 after selling out during the quarter.
  • EcoR1 Capital sold 1,250,000 Verve Therapeutics shares in Q2 2025, an estimated $5.71M.
  • EcoR1 Capital first reported a position in Verve Therapeutics in Q2 2021 and held it in 11 quarters.
  • EcoR1 Capital's Verve Therapeutics position peaked at $17.4M in Q4 2023.
  • 175 funds tracked by Wall St. Rank held Verve Therapeutics as of Q2 2025.

Based on EcoR1 Capital's 13F filing for Q2 2025, filed 14 Aug 2025.